This modeling study uses international, multi-ethnic derivation and validation cohorts
of patients with biopsy-proven IgA nephropathy to evaluate a risk-prediction tool
for 50% decline in kidney function or end-stage renal disease. How can we better predict,
at the time of kidney biopsy, the risk of a 50% decline in kidney function or end-stage
renal disease in patients with IgA nephropathy? Large international multiethnic cohorts
including 3927 patients were enrolled to both derive and externally validate 2 prediction
models, one that included patient race/ethnicity, and one that did not. Both models
outperformed clinical measures for prediction of kidney disease progression and patient
risk stratification. The 2 prediction models were shown to be accurate and validated
methods to help clinicians improve management and treatment of IgA nephropathy in
multi-ethnic cohorts and may aid international researchers in trial recruitment. Although
IgA nephropathy (IgAN) is the most common glomerulonephritis in the world, there is
no validated tool to predict disease progression. This limits patient-specific risk
stratification and treatment decisions, clinical trial recruitment, and biomarker
validation. To derive and externally validate a prediction model for disease progression
in IgAN that can be applied at the time of kidney biopsy in multiple ethnic groups
worldwide. We derived and externally validated a prediction model using clinical and
histologic risk factors that are readily available in clinical practice. Large, multi-ethnic
cohorts of adults with biopsy-proven IgAN were included from Europe, North America,
China, and Japan. Cox proportional hazards models were used to analyze the risk of
a 50% decline in estimated glomerular filtration rate (eGFR) or end-stage kidney disease,
and were evaluated using the R 2 D measure, Akaike information criterion (AIC),
C statistic, continuous net reclassification improvement (NRI), integrated discrimination
improvement (IDI), and calibration plots. The study included 3927 patients; mean age,
35.4 (interquartile range, 28.0-45.4) years; and 2173 (55.3%) were men. The following
prediction models were created in a derivation cohort of 2781 patients: a clinical
model that included eGFR, blood pressure, and proteinuria at biopsy; and 2 full models
that also contained the MEST histologic score, age, medication use, and either racial/ethnic
characteristics (white, Japanese, or Chinese) or no racial/ethnic characteristics,
to allow application in other ethnic groups. Compared with the clinical model, the
full models with and without race/ethnicity had better R 2 D (26.3% and 25.3%, respectively,
vs 20.3%) and AIC (6338 and 6379, respectively, vs 6485), significant increases in
C statistic from 0.78 to 0.82 and 0.81, respectively (ΔC, 0.04; 95% CI, 0.03-0.04
and ΔC, 0.03; 95% CI, 0.02-0.03, respectively), and significant improvement in reclassification
as assessed by the NRI (0.18; 95% CI, 0.07-0.29 and 0.51; 95% CI, 0.39-0.62, respectively)
and IDI (0.07; 95% CI, 0.06-0.08 and 0.06; 95% CI, 0.05-0.06, respectively). External
validation was performed in a cohort of 1146 patients. For both full models, the C
statistics (0.82; 95% CI, 0.81-0.83 with race/ethnicity; 0.81; 95% CI, 0.80-0.82 without
race/ethnicity) and R 2 D (both 35.3%) were similar or better than in the validation
cohort, with excellent calibration. In this study, the 2 full prediction models were
shown to be accurate and validated methods for predicting disease progression and
patient risk stratification in IgAN in multi-ethnic cohorts, with additional applications
to clinical trial design and biomarker research.